US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NeOnc Technologies Holdings

3.62

-0.4500-11.06%

Volume:299.19K

Turnover:1.09M

Market Cap:94.17M

PE:-1.69

High:4.00

Open:4.00

Low:3.46

Close:4.07

52wk High:12.99

52wk Low:3.01

Shares:26.01M

Float Shares:9.16M

Volume Ratio:1.64

T/O Rate:3.27%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.1361

EPS(LYR):-3.2036

ROE:--

ROA:-634.99%

PB:-4.35

PE(LYR):-1.13

Loading ...

Overview Company News Filings

The Nose Knows: Why NeOnc’s Patent Portfolio Could Make NTHI More Than a One-Drug Biotech

U.S. Stocks on the MOVE-Sutro Biopharma, Humacyte

Neonc Technologies - no Major Toxicities Reported in Phase 2a Neo100 Cohort

THOMSON REUTERS

Targeting The Mutant: NTHI’s NEO100 Data Could Open a New Front in the Fight Against Brain Cancer

NeOnc Technologies Says Phase 2a Trial of Intranasal NEO100 Met Progression-Free Survival Primary Endpoint

MT Newswires Live

NeOnc Technologies Says Brain Tumor Drug Trial Met Primary Endpoint

NeOnc Rises as Experimental Brain Cancer Therapy Meets Main Study Goal

NeOnc Reports Phase 2a Neo100 Trial Hits Six-Month PFS Endpoint in Recurrent IDH1-Mutant High-Grade Glioma

Neonc Technologies - no Major Toxicities Reported; Adverse Events Predominantly Low-Grade

THOMSON REUTERS

Neonc Technologies Reports Positive Topline Phase 2a Results for Intranasal Neo100 in Recurrent Idh1-Mutant High-Grade Glioma

THOMSON REUTERS

Neonc Technologies - Median Overall Survival Reported at 26.09 Months; 86.7% Alive at Six Months

THOMSON REUTERS

Neonc Technologies - Phase 2a Study Meets Primary Endpoint with Six-Month Pfs of 48.9%

THOMSON REUTERS

Neonc Technologies - to Request Type B FDA Meeting for Registrational Path

THOMSON REUTERS

NASDAQ Trade Halt Halt News Pending at 07:55 Am

NeOnc Heads into a High-Stakes Week as Highly Anticipated NEO100 Phase 2a Data Readout Nears

NeOnc Technologies Q2 EPS $(0.58) Misses $(0.15) Estimate

Benzinga Earnings

Neonc Reports Second Quarter 2026 Financial Results and Confirms August 12 Topline Phase 2a Neo100 Data Readout

THOMSON REUTERS

Neonc Technologies - Q2 2026 Net Loss $14.20 Mln or $(0.58) Per Diluted Share

THOMSON REUTERS

Press Release: NeOnc Reports Second Quarter 2026 Financial Results and Confirms August 12 Topline Phase 2a Neo100 Data Readout

NeOnc Technologies Hosts Call on Phase 2a Topline Data for Intranasal Neo100 in Recurrent IDH1-Mutant Glioma

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigreclipse.com/stock/NTHI/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NTHI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NTHI\",,,,,undefined,":{"symbol":"NTHI","market":"US","secType":"STK","nameCN":"NeOnc Technologies Holdings","latestPrice":3.62,"timestamp":1788984000000,"preClose":4.07,"halted":0,"volume":299193,"delay":0,"changeRate":-0.1105651105651106,"floatShares":9155900,"shares":26013100,"eps":-2.136127,"marketStatus":"Pre-Mkt","change":-0.45,"latestTime":"09-10 05:09:07 EDT","open":4,"high":4,"low":3.46,"amount":1094346.4778151,"amplitude":0.132678,"askPrice":4,"askSize":100,"bidPrice":3.29,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-2.136127,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789047000000},"marketStatusCode":1,"adr":0,"listingDate":1711512000000,"exchange":"NASDAQ","adjPreClose":3.62,"postHourTrading":{"tag":"盘后","latestPrice":3.69,"preClose":3.62,"latestTime":"19:59 EDT","volume":287,"amount":1055.1024,"timestamp":1788998345404,"change":0.07,"changeRate":0.019337,"amplitude":0.019337},"volumeRatio":1.6442536608190523},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NTHI\",,,,,undefined,":{"symbol":"NTHI","floatShares":9155900,"roa":"-634.99%","roe":"--","lyrEps":-3.203615,"volumeRatio":1.6442536608190523,"shares":26013100,"dividePrice":0,"high":4,"amplitude":0.132678,"preClose":4.07,"low":3.46,"week52Low":3.005,"pbRate":"-4.35","psRate":"2354.77","week52High":12.99,"institutionHeld":0,"latestPrice":3.62,"eps":-2.136127,"divideRate":0,"volume":299193,"delay":0,"ttmEps":-2.136127,"open":4,"prevYearClose":8.27,"prevWeekClose":5.03,"prevMonthClose":4.94,"prevQuarterClose":4.53,"fiveDayClose":4.73,"twentyDayClose":4.35,"sixtyDayClose":4.75},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NTHI\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-10","symbol":"NTHI","fiscalQuarterEnding":"2026/06","expectedEps":-0.16,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786334400000,"reportTimeType":"pre","actualEps":-0.58},{"market":"US","date":"2026-05-15","symbol":"NTHI","fiscalQuarterEnding":"2026/03","expectedEps":-0.3,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778817600000,"reportTimeType":"post","actualEps":-0.38},{"market":"US","date":"2026-03-31","symbol":"NTHI","fiscalQuarterEnding":"2025/12","expectedEps":-0.37,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1774929600000,"reportTimeType":"pre","actualEps":-0.72},{"market":"US","date":"2025-11-14","symbol":"NTHI","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1763096400000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-08-18","symbol":"NTHI","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1755489600000,"reportTimeType":"","actualEps":-0.3}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NTHI\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NTHI\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":3,"updateTime":1779249600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NTHI\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NTHI","date":"2026-09-09","current":-1.694656,"percent":0.843407,"low":-26.074295,"twenty":-4.190105,"median":-3.072053,"eighty":-2.270701,"high":-1.357276,"avg":-3.965825,"sd":3.234928,"marketCap":101167265},"quantilePoints":[{"date":"2024-03-28","current":-18.899455,"twenty":-18.899455,"median":-18.899455,"eighty":-18.899455,"marketCap":282000000},{"date":"2025-03-28","current":-18.905834,"twenty":-19.009816,"median":-18.905834,"eighty":-18.902007,"marketCap":224950380},{"date":"2025-04-04","current":-15.093157,"twenty":-20.260752,"median":-18.902645,"eighty":-16.151884,"marketCap":179585386},{"date":"2025-04-11","current":-14.179375,"twenty":-19.504518,"median":-17.739974,"eighty":-15.124667,"marketCap":168712785},{"date":"2025-04-17","current":-11.028403,"twenty":-19.044476,"median":-15.392499,"eighty":-12.855967,"marketCap":131221055},{"date":"2025-04-25","current":-9.437162,"twenty":-18.904558,"median":-14.667776,"eighty":-10.965384,"marketCap":112287731},{"date":"2025-05-02","current":-8.444606,"twenty":-18.667559,"median":-12.525115,"eighty":-9.437162,"marketCap":100477836},{"date":"2025-05-09","current":-10.398208,"twenty":-17.342951,"median":-11.028403,"eighty":-9.33318,"marketCap":123722709},{"date":"2025-05-16","current":-2.933338,"twenty":-15.682389,"median":-10.398208,"eighty":-8.444606,"marketCap":137753858},{"date":"2025-05-23","current":-2.969802,"twenty":-15.348385,"median":-9.44504,"eighty":-3.015179,"marketCap":139466268},{"date":"2025-05-30","current":-2.99006,"twenty":-15.171931,"median":-9.437162,"eighty":-2.969802,"marketCap":140417606},{"date":"2025-06-06","current":-3.034627,"twenty":-15.093157,"median":-9.311123,"eighty":-2.969802,"marketCap":142510552},{"date":"2025-06-13","current":-2.593006,"twenty":-14.242395,"median":-8.476116,"eighty":-2.937389,"marketCap":121771366},{"date":"2025-06-20","current":-1.928548,"twenty":-14.191979,"median":-7.853798,"eighty":-2.929004,"marketCap":90567453},{"date":"2025-06-27","current":-1.616577,"twenty":-12.855967,"median":-3.034627,"eighty":-2.802066,"marketCap":75916836},{"date":"2025-07-03","current":-2.362066,"twenty":-12.222621,"median":-3.010317,"eighty":-2.532985,"marketCap":110926104},{"date":"2025-07-11","current":-1.977167,"twenty":-11.425425,"median":-2.998163,"eighty":-2.362066,"marketCap":92850666},{"date":"2025-07-18","current":-1.786743,"twenty":-11.028403,"median":-2.99006,"eighty":-2.222692,"marketCap":83908082},{"date":"2025-07-25","current":-1.904238,"twenty":-10.981139,"median":-2.959854,"eighty":-1.949616,"marketCap":89425847},{"date":"2025-08-01","current":-1.98527,"twenty":-10.618776,"median":-2.937389,"eighty":-1.970684,"marketCap":93231202},{"date":"2025-08-08","current":-1.944754,"twenty":-10.133526,"median":-2.931642,"eighty":-1.939892,"marketCap":91328524},{"date":"2025-08-15","current":-2.102765,"twenty":-9.654579,"median":-2.909028,"eighty":-1.943134,"marketCap":98748967},{"date":"2025-08-22","current":-2.604584,"twenty":-9.443464,"median":-2.799635,"eighty":-1.954478,"marketCap":110548110},{"date":"2025-08-29","current":-3.15078,"twenty":-9.437162,"median":-2.795584,"eighty":-1.970684,"marketCap":133730643},{"date":"2025-09-05","current":-3.371966,"twenty":-9.437162,"median":-2.876616,"eighty":-1.980408,"marketCap":143118611},{"date":"2025-09-12","current":-4.405675,"twenty":-9.43086,"median":-2.918386,"eighty":-1.98527,"marketCap":186992991},{"date":"2025-09-19","current":-5.457439,"twenty":-9.377293,"median":-2.933338,"eighty":-1.993373,"marketCap":231633736},{"date":"2025-09-26","current":-4.681029,"twenty":-9.292217,"median":-2.939656,"eighty":-2.005528,"marketCap":198680053},{"date":"2025-10-03","current":-5.141458,"twenty":-8.961365,"median":-2.969802,"eighty":-2.008769,"marketCap":218222354},{"date":"2025-10-10","current":-5.407785,"twenty":-8.482417,"median":-2.99006,"eighty":-2.016872,"marketCap":229526233},{"date":"2025-10-17","current":-4.730683,"twenty":-8.444606,"median":-3.002214,"eighty":-2.039561,"marketCap":200787556},{"date":"2025-10-24","current":-3.769199,"twenty":-7.97196,"median":-3.022472,"eighty":-2.067922,"marketCap":159978635},{"date":"2025-10-31","current":-4.590749,"twenty":-7.105442,"median":-3.15078,"eighty":-2.071973,"marketCap":194848230},{"date":"2025-11-07","current":-4.446301,"twenty":-6.304447,"median":-3.298614,"eighty":-2.085748,"marketCap":188717312},{"date":"2025-11-14","current":-4.053582,"twenty":-5.457439,"median":-3.638293,"eighty":-2.120592,"marketCap":172048879},{"date":"2025-11-21","current":-2.32457,"twenty":-5.457439,"median":-3.482559,"eighty":-2.150574,"marketCap":113613569},{"date":"2025-11-28","current":-3.566132,"twenty":-5.449314,"median":-3.447134,"eighty":-2.162729,"marketCap":174295011},{"date":"2025-12-05","current":-3.725512,"twenty":-5.41591,"median":-3.522302,"eighty":-2.193521,"marketCap":182084733},{"date":"2025-12-12","current":-3.733481,"twenty":-5.411396,"median":-3.568124,"eighty":-2.214589,"marketCap":182474219},{"date":"2025-12-19","current":-2.797122,"twenty":-5.405979,"median":-3.570116,"eighty":-2.278603,"marketCap":136709607},{"date":"2025-12-26","current":-3.327062,"twenty":-5.398757,"median":-3.566132,"eighty":-2.301292,"marketCap":162610430},{"date":"2026-01-02","current":-3.295186,"twenty":-5.391535,"median":-3.474488,"eighty":-2.319914,"marketCap":161052485},{"date":"2026-01-09","current":-3.916768,"twenty":-5.368062,"median":-3.548202,"eighty":-2.33285,"marketCap":191432398},{"date":"2026-01-16","current":-3.466519,"twenty":-5.344589,"median":-3.566132,"eighty":-2.344813,"marketCap":169426436},{"date":"2026-01-23","current":-3.486442,"twenty":-5.296741,"median":-3.53824,"eighty":-2.348861,"marketCap":170400151},{"date":"2026-01-30","current":-3.486442,"twenty":-5.229933,"median":-3.552186,"eighty":-2.357204,"marketCap":170400151},{"date":"2026-02-06","current":-3.681683,"twenty":-5.174862,"median":-3.566132,"eighty":-2.362066,"marketCap":179942559},{"date":"2026-02-13","current":-4.169784,"twenty":-5.146875,"median":-3.570116,"eighty":-2.389761,"marketCap":203798580},{"date":"2026-02-20","current":-3.426674,"twenty":-5.12611,"median":-3.574101,"eighty":-2.410019,"marketCap":167479005},{"date":"2026-02-27","current":-4.020365,"twenty":-5.049824,"median":-3.613946,"eighty":-2.417236,"marketCap":196495717},{"date":"2026-03-06","current":-3.835101,"twenty":-4.966315,"median":-3.638073,"eighty":-2.428412,"marketCap":187440892},{"date":"2026-03-13","current":-3.660224,"twenty":-4.933814,"median":-3.653791,"eighty":-2.438178,"marketCap":178893747},{"date":"2026-03-20","current":-3.253532,"twenty":-4.851659,"median":-3.642057,"eighty":-2.502974,"marketCap":159016664},{"date":"2026-03-27","current":-2.981402,"twenty":-4.767698,"median":-3.621915,"eighty":-2.597637,"marketCap":145716276},{"date":"2026-04-02","current":-1.961459,"twenty":-4.735197,"median":-3.603287,"eighty":-2.595322,"marketCap":121897269},{"date":"2026-04-10","current":-1.961307,"twenty":-4.734294,"median":-3.574101,"eighty":-2.414974,"marketCap":121887825},{"date":"2026-04-17","current":-2.012281,"twenty":-4.720752,"median":-3.566132,"eighty":-2.352342,"marketCap":125055639},{"date":"2026-04-24","current":-1.920085,"twenty":-4.679223,"median":-3.562148,"eighty":-2.305948,"marketCap":119325998},{"date":"2026-05-01","current":-1.771769,"twenty":-4.657556,"median":-3.53824,"eighty":-2.205893,"marketCap":110108750},{"date":"2026-05-08","current":-2.630543,"twenty":-4.597971,"median":-3.502161,"eighty":-2.162729,"marketCap":163478290},{"date":"2026-05-15","current":-2.213061,"twenty":-4.588041,"median":-3.478473,"eighty":-2.19289,"marketCap":137533354},{"date":"2026-05-22","current":-3.511755,"twenty":-4.577207,"median":-3.486442,"eighty":-2.19724,"marketCap":135694649},{"date":"2026-05-29","current":-3.138303,"twenty":-4.577207,"median":-3.483777,"eighty":-2.19881,"marketCap":121264435},{"date":"2026-06-05","current":-2.990888,"twenty":-4.568179,"median":-3.474488,"eighty":-2.200003,"marketCap":115568297},{"date":"2026-06-12","current":-2.948302,"twenty":-4.559151,"median":-3.434643,"eighty":-2.209008,"marketCap":113922747},{"date":"2026-06-18","current":-3.151407,"twenty":-4.512205,"median":-3.406752,"eighty":-2.21225,"marketCap":121770758},{"date":"2026-06-26","current":-2.954853,"twenty":-4.486024,"median":-3.393823,"eighty":-2.226031,"marketCap":114175908},{"date":"2026-07-02","current":-2.922095,"twenty":-4.474288,"median":-3.367616,"eighty":-2.229383,"marketCap":112910100},{"date":"2026-07-10","current":-3.013469,"twenty":-4.460746,"median":-3.339093,"eighty":-2.231778,"marketCap":116440808},{"date":"2026-07-17","current":-2.181241,"twenty":-4.449912,"median":-3.327062,"eighty":-2.231778,"marketCap":84283436},{"date":"2026-07-24","current":-2.436279,"twenty":-4.432759,"median":-3.283232,"eighty":-2.231778,"marketCap":94138114},{"date":"2026-07-31","current":-2.342317,"twenty":-4.416509,"median":-3.25181,"eighty":-2.244708,"marketCap":90507443},{"date":"2026-08-07","current":-2.349029,"twenty":-4.389966,"median":-3.211511,"eighty":-2.26624,"marketCap":90766777},{"date":"2026-08-14","current":-1.763689,"twenty":-4.333179,"median":-3.181853,"eighty":-2.231004,"marketCap":83246101},{"date":"2026-08-21","current":-2.401422,"twenty":-4.279913,"median":-3.15078,"eighty":-2.244708,"marketCap":113347108},{"date":"2026-08-28","current":-2.42512,"twenty":-4.273416,"median":-3.115982,"eighty":-2.26624,"marketCap":114465665},{"date":"2026-09-04","current":-2.522546,"twenty":-4.230747,"median":-3.083785,"eighty":-2.27546,"marketCap":119064177},{"date":"2026-09-09","current":-2.143374,"twenty":-4.190105,"median":-3.072053,"eighty":-2.270701,"marketCap":101167265}],"updateTime":1789031347298},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NTHI\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2659164587","title":"The Nose Knows: Why NeOnc’s Patent Portfolio Could Make NTHI More Than a One-Drug Biotech","url":"https://stock-news.laohu8.com/highlight/detail?id=2659164587","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659164587?lang=en_us&edition=fundamental","pubTime":"2026-08-14 02:31","pubTimestamp":1786645860,"startTime":"0","endTime":"0","summary":"Stunning Brain-Cancer Data Are Putting NeOnc’s Nose-to-Brain Delivery Platform, and Its Broader Potential, Front and CenterDENVER, Aug.  13, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings’ (NASD","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/13/3344837/0/en/the-nose-knows-why-neonc-s-patent-portfolio-could-make-nthi-more-than-a-one-drug-biotech.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4581","BK4588","NTHI","BK4007","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659092299","title":"U.S. Stocks on the MOVE-Sutro Biopharma, Humacyte","url":"https://stock-news.laohu8.com/highlight/detail?id=2659092299","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659092299?lang=en_us&edition=fundamental","pubTime":"2026-08-13 00:17","pubTimestamp":1786551433,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Sutro Biopharma, HumacyteAugust 12 (Reuters)-Wall Street's main indexes rose on Wednesday, with the Nasdaq outperforming peers as upbeat earnings from AI infrastructure fi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL6N4490YK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CORD","BETA","EAT","LITE","DPRE","NBIS","ABSI","NCMI","PFGC","TSHA","SMCL","OPLN","CHTR","NBIZ","EGGY","WXM","LUMA","SLXN","SVV","SMCI","TAN","TECH","EROC","DFTX","NTHI","LOCL","LQDA","STRO","ALT","ANNX","HUMA","TPL","TRMB","CIEN","CAVA","NBIX","FSLR","HRB","LAZR","BIVI","GAP","SMMT","SLN","SLNCF","SMWB","UFO","UAMY","CRWV","O","OFAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658908157","title":"Neonc Technologies - no Major Toxicities Reported in Phase 2a Neo100 Cohort","url":"https://stock-news.laohu8.com/highlight/detail?id=2658908157","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658908157?lang=en_us&edition=fundamental","pubTime":"2026-08-12 21:38","pubTimestamp":1786541937,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nFWN44914H:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NTHI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658590389","title":"Targeting The Mutant: NTHI’s NEO100 Data Could Open a New Front in the Fight Against Brain Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2658590389","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658590389?lang=en_us&edition=fundamental","pubTime":"2026-08-12 21:38","pubTimestamp":1786541880,"startTime":"0","endTime":"0","summary":"DALLAS, Aug.  12, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings (NASDAQ: NTHI) has delivered the kind of clinical update that can change the conversation around a small biotechnology company: i","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/12/3343786/0/en/targeting-the-mutant-nthi-s-neo100-data-could-open-a-new-front-in-the-fight-against-brain-cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NTHI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658977252","title":"NeOnc Technologies Says Phase 2a Trial of Intranasal NEO100 Met Progression-Free Survival Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2658977252","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658977252?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:43","pubTimestamp":1786538586,"startTime":"0","endTime":"0","summary":"NeOnc Technologies  said Wednesday the phase 2a portion of its trial of intranasal NEO100 in recurrent or progressive IDH1-mutant high-grade glioma met its primary endpoint with a six-month progression-free survival of 48.9%.The trial further demonstrated a median overall survival of 26.09 months, with 12 deaths among 24 patients. Overall survival was 86.7% at six months, 60.9% at 12 months and 54.1% at 24 months, according to the company.Looking ahead, NeOnc Technologies said it will request a type B meeting with the US Food and Drug Administration to align on a registrational development path for NEO100 in recurrent IDH1-mutant high-grade glioma.Shares of the company were up over 1% in Wednesday premarket activity.Price: 4.37, Change: +0.02, Percent Change: +1.15","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","NTHI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658977122","title":"NeOnc Technologies Says Brain Tumor Drug Trial Met Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2658977122","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658977122?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:35","pubTimestamp":1786538100,"startTime":"0","endTime":"0","summary":"NeOnc Technologies said its recent study of a brain tumor treatment met its primary endpoint.Nearly 49% of patients with recurrent or progressive IDH1-mutant glioma brain tumors had six-month progression-free survival during the study, the biopharmaceutical company said Wednesday.That compared with a 20% benchmark rate set before the trial began.The treatment, known as NEO100, was administered through the nose by patients at home, with no major toxicities reported. Administering the treatment through the nose allows it to pass through the blood-brain barrier, which has been a challenge in treating brain cancer.Median overall survival was 26 months, with 12 deaths among the 24 patients. Overall survival was 87% at six months, 61% at 12 months and 54% at 24 months. Of the original 24 patients, five remain in active treatment.NeOnc's next priority is to engage with the Food and Drug Administration and align on the best path toward a registrational study, Chief Executive Amir Heshmatpour s","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658229972","title":"NeOnc Rises as Experimental Brain Cancer Therapy Meets Main Study Goal","url":"https://stock-news.laohu8.com/highlight/detail?id=2658229972","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658229972?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:15","pubTimestamp":1786536931,"startTime":"0","endTime":"0","summary":"BUZZ-NeOnc rises as experimental brain cancer therapy meets main study goal** Shares of NeOnc TechnologiesNTHI.Orise 12.4% to $4.89 premarket** The clinical-stage brain cancer drug developer says expe","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL4N4490WZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658196972","title":"NeOnc Reports Phase 2a Neo100 Trial Hits Six-Month PFS Endpoint in Recurrent IDH1-Mutant High-Grade Glioma","url":"https://stock-news.laohu8.com/highlight/detail?id=2658196972","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658196972?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:08","pubTimestamp":1786536508,"startTime":"0","endTime":"0","summary":"NeOnc reports Phase 2a NEO100 trial hits six-month PFS endpoint in recurrent IDH1-mutant high-grade gliomaNeOnc reported positive topline Phase 2a results for intranasal NEO100 in recurrent IDH1-mutan","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL8pBYcT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","SG9999014039.USD","BCDF","NTHI","LU2210149790.SGD","IE00BN0W2W23.USD","SG9999014005.SGD","SG9999014013.SGD","LU0314104364.USD","BK4112","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","NDAQ","LU2210150020.SGD","IE00B3QW5Z07.USD","BK4007","BK4588","LU2095319765.USD","IE00BKPKM429.USD","SG9999014021.USD","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658972591","title":"Neonc Technologies - no Major Toxicities Reported; Adverse Events Predominantly Low-Grade","url":"https://stock-news.laohu8.com/highlight/detail?id=2658972591","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658972591?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:00","pubTimestamp":1786536004,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nTUA2KTJGZ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NTHI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658972590","title":"Neonc Technologies Reports Positive Topline Phase 2a Results for Intranasal Neo100 in Recurrent Idh1-Mutant High-Grade Glioma","url":"https://stock-news.laohu8.com/highlight/detail?id=2658972590","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658972590?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:00","pubTimestamp":1786536004,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nTUA2KTJGZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NTHI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658972535","title":"Neonc Technologies - Median Overall Survival Reported at 26.09 Months; 86.7% Alive at Six Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2658972535","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658972535?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:00","pubTimestamp":1786536004,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nTUA2KTJGZ:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NTHI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658725879","title":"Neonc Technologies - Phase 2a Study Meets Primary Endpoint with Six-Month Pfs of 48.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658725879","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658725879?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:00","pubTimestamp":1786536004,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nTUA2KTJGZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NTHI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658563972","title":"Neonc Technologies - to Request Type B FDA Meeting for Registrational Path","url":"https://stock-news.laohu8.com/highlight/detail?id=2658563972","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658563972?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:00","pubTimestamp":1786536004,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nTUA2KTJGZ:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NTHI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658866972","title":"NASDAQ Trade Halt Halt News Pending at 07:55 Am","url":"https://stock-news.laohu8.com/highlight/detail?id=2658866972","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658866972?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:55","pubTimestamp":1786535700,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALTHALT NEWS PENDING AT 07:55 AM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nAQN2MEA1S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658953571","title":"NeOnc Heads into a High-Stakes Week as Highly Anticipated NEO100 Phase 2a Data Readout Nears","url":"https://stock-news.laohu8.com/highlight/detail?id=2658953571","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658953571?lang=en_us&edition=fundamental","pubTime":"2026-08-10 22:34","pubTimestamp":1786372440,"startTime":"0","endTime":"0","summary":"Topline Results from Intranasal NEO100 in Recurrent IDH1-mutant High-grade Glioma could mark a Major Clinical Catalyst for NeOncDENVER, Aug.  10, 2026 (GLOBE NEWSWIRE) -- (247mnn.com) –NeOnc Technolog","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/10/3341958/0/en/neonc-heads-into-a-high-stakes-week-as-highly-anticipated-neo100-phase-2a-data-readout-nears.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","CNS","BBB","IND","NTHI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658939728","title":"NeOnc Technologies Q2 EPS $(0.58) Misses $(0.15) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2658939728","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658939728?lang=en_us&edition=fundamental","pubTime":"2026-08-10 21:01","pubTimestamp":1786366911,"startTime":"0","endTime":"0","summary":"NeOnc Technologies (NASDAQ:NTHI) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.15) by 286.67 percent. This is a 93.33 percent decrease over losses of $(0.30) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61073646/neonc-technologies-q2-eps-0-58-misses-0-15-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NTHI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658393920","title":"Neonc Reports Second Quarter 2026 Financial Results and Confirms August 12 Topline Phase 2a Neo100 Data Readout","url":"https://stock-news.laohu8.com/highlight/detail?id=2658393920","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658393920?lang=en_us&edition=fundamental","pubTime":"2026-08-10 21:00","pubTimestamp":1786366802,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nTUABL69V6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NTHI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658345931","title":"Neonc Technologies - Q2 2026 Net Loss $14.20 Mln or $(0.58) Per Diluted Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2658345931","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658345931?lang=en_us&edition=fundamental","pubTime":"2026-08-10 21:00","pubTimestamp":1786366802,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nTUABL69V6:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NTHI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658939707","title":"Press Release: NeOnc Reports Second Quarter 2026 Financial Results and Confirms August 12 Topline Phase 2a Neo100 Data Readout","url":"https://stock-news.laohu8.com/highlight/detail?id=2658939707","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658939707?lang=en_us&edition=fundamental","pubTime":"2026-08-10 21:00","pubTimestamp":1786366800,"startTime":"0","endTime":"0","summary":"for NEO100, covering all three NEO100 programs across adult Phase 1. through Phase 2, as well as pediatric studies. The authorization extends. NeOnc's UAE footprint beyond NEO212 and complements ongoing U.S.development, where NEO100 holds FDA Orphan Drug, Fast Track and Rare. -- NEO212 UAE IND Approval: Also in June, the Company secured UAE IND. approval for NEO212, enabling Phase 2 evaluation of the Company's oral. perillyl alcohol-temozolomide conjugate in the United Arab Emirates. The","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4555","NTHI","BK4604","TM","BK4588","BK4007","03160","BK4099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658360489","title":"NeOnc Technologies Hosts Call on Phase 2a Topline Data for Intranasal Neo100 in Recurrent IDH1-Mutant Glioma","url":"https://stock-news.laohu8.com/highlight/detail?id=2658360489","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658360489?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:31","pubTimestamp":1786365104,"startTime":"0","endTime":"0","summary":"NeOnc Technologies hosts call on Phase 2a topline data for intranasal NEO100 in recurrent IDH1-mutant gliomaNeOnc Technologies scheduled an Aug. 12, 2026 investor call to present topline Phase 2a resu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nNDL9fbgfd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","BK4585","BK4007","IE00B64PRP62.GBP","SG9999014013.SGD","BK4588","IE00BN0W2W23.USD","SG9999014005.SGD","LU2210150020.SGD","LU2210149790.SGD","LU2095319765.USD","IE00BKPKM429.USD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","NTHI","BCDF","BK4112","SG9999014021.USD","IE00B3QW5Z07.USD","SG9999014039.USD","NDAQ","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":2,"totalSize":106,"code":"91000000","status":"200"}]}}